During the past decade, Hopital Lapeyronie; Nephrologie conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital Lapeyronie; Nephrologie" #1 collaborator was "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Hopital Lapeyronie; Nephrologie" are "Atypical Hemolytic Uremic Syndrome" (1 trials) and "Cytomegalovirus Infections" (1 trials). Many other conditions were trialed in "Hopital Lapeyronie; Nephrologie" in a lesser frequency.

Most popular intervention types in "Hopital Lapeyronie; Nephrologie" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Crovalimab" (1 trials) and "Valganciclovir" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hopital Lapeyronie; Nephrologie" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Hopital Lapeyronie; Nephrologie". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Hopital Lapeyronie; Nephrologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Hopital Lapeyronie; Nephrologie, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".